Latest Capital Strategy News

EMVision Medical Devices’ latest Share Purchase Plan has attracted applications exceeding its initial $1 million target, with limited oversubscription capacity remaining ahead of the October 23 closing date.

QBE Insurance Group has announced the redemption of its USD 300 million 6.10% fixed rate subordinated notes due 2045, marking a notable step in its capital management strategy with regulatory approval secured.

CuFe Ltd has raised $5.4 million through a strategic placement to fund exploration and feasibility studies at its Tennant Creek Copper/Gold project, including a focus on critical mineral bismuth.

Bank of Queensland’s August 2025 APRA Basel III Pillar 3 report reveals stable capital ratios and robust liquidity metrics, underscoring its disciplined risk management amid portfolio growth.

EDU Holdings Limited is set to renew its on-market share buyback program, aiming to repurchase up to 14.4 million shares over the next year, continuing its strategy to enhance shareholder value.

Gryphon Capital Income Trust has announced a substantial non-underwritten Unit Purchase Plan, offering existing unitholders a chance to increase their stake at a slight discount. The offer aims to raise up to A$337 million to support its portfolio strategy.

Dotz Nano Limited has raised an additional A$460,000 through unsecured loans, bringing total funding under this facility to A$1.2 million to support working capital needs.

Ramelius Resources has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.05 per share for FY2025, alongside details of its Dividend Reinvestment Plan pricing.

CONNEQT Health has raised $2 million through a convertible note facility with a director-owned entity, providing fresh capital to support its growth plans. Shareholder approval will be key to unlocking the full benefits of this funding.

Australian Vanadium Limited has locked in a US$10 million secured loan from major shareholder RCF to advance its flagship vanadium project and prepare for a significant government battery storage tender.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.

The Calmer Co. has secured $700,000 in the first tranche of a $1.4 million convertible note raise, welcoming US distributor Applied Food Sciences as a strategic investor to fuel its expanding wholesale presence.